2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.13 (Poster) Healthcare Utilization Amongst Patients with NSCLC Before and After Testing with a Host Immune Classifier (HIC) in a Real-World Setting

PP01.13 (Poster) Healthcare Utilization Amongst Patients with NSCLC Before and After Testing with a Host Immune Classifier (HIC) in a Real-World Setting

Back to course

Pdf Summary

A study presented at the IASLC 2023 North America Conference on Lung Cancer examined the healthcare utilization of patients with non-small cell lung cancer (NSCLC) before and after testing with a Host Immune Classifier (HIC), a blood-based immune profiling test. The study aimed to determine if there were any differences in healthcare resource utilization (HCRU) and costs among patients after using the HIC.<br /><br />The results of the study showed that there were no significant differences between patients with a HIC-Hot (HIC-H) or HIC-Cold (HIC-C) categorization in terms of lung-cancer specific treatments. However, there were some differences in the utilization of other medications. Patients in the HIC-H cohort had a significantly lower number of opioid prescriptions filled, and they utilized granulocyte colony-stimulating factor and asthma medications less frequently compared to the HIC-C cohort.<br /><br />In terms of overall healthcare utilization, the study found that HIC-C patients had higher HCRU pre-index, including more visits with primary care physicians and oncologists. However, there were no significant differences in post-index utilization between the two cohorts.<br /><br />The study also analyzed imaging and intervention utilization. There were no significant differences in the number of imaging scans or interventions between the HIC-H and HIC-C cohorts in the pre-index period. But in the post-index period, HIC-H patients had a significantly longer time to their first scan and were more likely to undergo lobectomy, while HIC-C patients were more likely to undergo radiation.<br /><br />These findings suggest that early identification of HIC status may help identify patients who may require additional support and interventions. The study concluded that using the HIC test could provide valuable information about a patient's immune response to lung cancer and help inform treatment decisions.

Asset Subtitle

Kimberly Le

Keywords

IASLC 2023

lung cancer

Host Immune Classifier

HIC

healthcare utilization

opioid prescriptions

primary care physicians

imaging scans

interventions

immune response